Biogen Ma Inc. - Net Worth and Insider Trading

Biogen Ma Inc. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Biogen Ma Inc. owns 3 companies in total, including Denali Therapeutics Inc (DNLI) , Sangamo Therapeutics Inc (SGMO) , and Sage Therapeutics Inc (SAGE) .

Click here to see the complete history of Biogen Ma Inc.’s form 4 insider trades.

Insider Ownership Summary of Biogen Ma Inc.

Ticker	Comapny	Transaction Date	Type of Owner
DNLI	Denali Therapeutics Inc	2020-09-22	10 percent owner
SGMO	Sangamo Therapeutics Inc	2021-11-26	10 percent owner
SAGE	Sage Therapeutics Inc	2020-12-31	10 percent owner

Biogen Ma Inc. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Biogen Ma Inc. Ownership Network

Ownership Network List of Biogen Ma Inc.

No Data

Ownership Network Relation of Biogen Ma Inc.

Biogen Ma Inc. Owned Company Details

What does Denali Therapeutics Inc do?

Who are the key executives at Denali Therapeutics Inc?

Biogen Ma Inc. is the 10 percent owner of Denali Therapeutics Inc. Other key executives at Denali Therapeutics Inc include CFO and Treasurer Steve E. Krognes , COO and Secretary Alexander O. Schuth , and Chief Medical Officer Carole Ho .

Denali Therapeutics Inc (DNLI) Insider Trades Summary

Over the past 18 months, Biogen Ma Inc. made no insider transaction in Denali Therapeutics Inc (DNLI). Other recent insider transactions involving Denali Therapeutics Inc (DNLI) include a net sale of 106,621 shares made by Alexander O. Schuth , a net sale of 42,800 shares made by Carole Ho , and a net sale of 186,802 shares made by Ryan J. Watts .

In summary, during the past 3 months, insiders sold 136,870 shares of Denali Therapeutics Inc (DNLI) in total and bought 0 shares, with a net sale of 136,870 shares. During the past 18 months, 480,892 shares of Denali Therapeutics Inc (DNLI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 480,892 shares.

Denali Therapeutics Inc (DNLI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Denali Therapeutics Inc Insider Transactions

No Available Data

What does Sangamo Therapeutics Inc do?

Who are the key executives at Sangamo Therapeutics Inc?

Biogen Ma Inc. is the 10 percent owner of Sangamo Therapeutics Inc. Other key executives at Sangamo Therapeutics Inc include 10 percent owner Biogen Inc. , SVP-Chief Development Officer Nathalie Dubois-stringfellow , and SVP & Gen. Counsel & Secretary Scott B. Willoughby .

Sangamo Therapeutics Inc (SGMO) Insider Trades Summary

Over the past 18 months, Biogen Ma Inc. made no insider transaction in Sangamo Therapeutics Inc (SGMO). Other recent insider transactions involving Sangamo Therapeutics Inc (SGMO) include a net sale of 6,000,000 shares made by Biogen Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of Sangamo Therapeutics Inc (SGMO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,000,000 shares of Sangamo Therapeutics Inc (SGMO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 6,000,000 shares.

Sangamo Therapeutics Inc (SGMO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sangamo Therapeutics Inc Insider Transactions

No Available Data

What does Sage Therapeutics Inc do?

Who are the key executives at Sage Therapeutics Inc?

Biogen Ma Inc. is the 10 percent owner of Sage Therapeutics Inc. Other key executives at Sage Therapeutics Inc include director & See Remarks Jeffrey M Jonas , Chief Medical Officer Laura Gault , and Chief Commercial Officer Christopher Benecchi .

Sage Therapeutics Inc (SAGE) Insider Trades Summary

Over the past 18 months, Biogen Ma Inc. made no insider transaction in Sage Therapeutics Inc (SAGE). Other recent insider transactions involving Sage Therapeutics Inc (SAGE) include a net purchase of 3,000 shares made by Elizabeth Barrett , a net purchase of 14,500 shares made by Barry E Greene , and a net sale of 11,643 shares made by Jeffrey M Jonas .

In summary, during the past 3 months, insiders sold 0 shares of Sage Therapeutics Inc (SAGE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 11,643 shares of Sage Therapeutics Inc (SAGE) were sold and 17,500 shares were bought by its insiders, resulting in a net purchase of 5,857 shares.

Sage Therapeutics Inc (SAGE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sage Therapeutics Inc Insider Transactions

No Available Data

Biogen Ma Inc. Mailing Address

Above is the net worth, insider trading, and ownership report for Biogen Ma Inc.. You might contact Biogen Ma Inc. via mailing address: 225 Binney Street, Cambridge Ma 02142.

Discussions on Biogen Ma Inc.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.